Novartis Investigative Site

Cauldfield, Victoria 3162

0 studies enrolling now · 2 studies all time

What they study most

Sporadic Inclusion Body Myositis

Studies at this site

• An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 — Completed
• Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients — Completed